Tumor–Host Cell Interactions in Ovarian Cancer: Pathways to Therapy Failure

Trends in Cancer

Volumn 3, Issue 2, 2017, Pages 137-148

  Pogge von Strandmann, Elke ^a   Reinartz, Silke ^a   Wager, Uwe ^b   Müller, Rolf ^a  

^a Fachbereich Medizin der Universitat Marburg   (Germany)

^b UNIVERSITY HOSPITAL MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA;

ADIPOCYTE; CANCER ASSOCIATED FIBROBLAST; CANCER CELL; CANCER RESISTANCE; CELL INTERACTION; CHEMOSENSITIZATION; EXOSOME; EXPERIMENTAL MODEL; HOST CELL; HUMAN; MOLECULAR INTERACTION; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TUMOR MICROENVIRONMENT; CANCER STEM CELL; CELL COMMUNICATION; DISEASE FREE SURVIVAL; DRUG EFFECT; DRUG RESISTANCE; FEMALE; GENETICS; METASTASIS; OVARY TUMOR; PATHOLOGY; TUMOR RECURRENCE;

CELL COMMUNICATION; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASTIC STEM CELLS; OVARIAN NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 85009754371     PISSN: 24058033     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trecan.2016.12.005     Document Type: Review

References (89)

1. 1 Lengyel, E., Ovarian cancer development and metastasis. Am. J. Pathol. 177 (2010), 1053–1064.
2. 2 Vaughan, S., et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat. Rev. Cancer 11 (2011), 719–725.
3. 3 Ahmed, N., Stenvers, K.L., Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research. Front. Oncol., 3, 2013, 256.
4. 4 Bowtell, D.D., et al. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat. Rev. Cancer 15 (2015), 668–679.
5. 5 Kipps, E., et al. Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. Nat. Rev. Cancer 13 (2013), 273–282.
6. 6 Reinartz, S., et al. A transcriptome-based global map of signaling pathways in the ovarian cancer microenvironment associated with clinical outcome. Genome Biol., 17, 2016, 108.
7. 7 Foster, R., et al. Ovarian cancer stem cells: working towards the root of stemness. Cancer Lett. 338 (2013), 147–157.
8. 8 Rizzo, S., et al. Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2. Mol. Cancer Ther. 10 (2011), 325–335.
9. 9 Kwon, M.J., Shin, Y.K., Regulation of ovarian cancer stem cells or tumor-initiating cells. Int. J. Mol. Sci. 14 (2013), 6624–6648.
10. 10 Zhu, X., Lang, J., The significance and therapeutic potential of PD-1 and its ligands in ovarian cancer: a systematic review. Gynecol. Oncol. 142 (2016), 184–189.
11. 11 Santoiemma, P.P., Powell, D.J. Jr., Tumor infiltrating lymphocytes in ovarian cancer. Cancer Biol. Ther. 16 (2015), 807–820.
12. 12 Wendler, F., et al. Extracellular vesicles swarm the cancer microenvironment: from tumor–stroma communication to drug intervention. Oncogene, 2016, 10.1038/onc.2016.253 Published online August 22, 2016.
13. 13 Melo, S.A., et al. Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis. Cancer Cell 26 (2014), 707–721.
14. 14 Bagnoli, M., et al. Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study. Lancet Oncol. 17 (2016), 1137–1146.
15. 15 Yang, D., et al. Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell 23 (2013), 186–199.
16. 16 Konecny, G.E., et al. Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer. J. Natl. Cancer Inst., 106, 2014, dju249.
17. 17 Luo, X., et al. Enrichment of ovarian cancer stem-like cells is associated with epithelial to mesenchymal transition through an miRNA-activated AKT pathway. Cell Prolif. 46 (2013), 436–446.
18. 18 Marchini, S., et al. Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer. Eur. J. Cancer 49 (2013), 520–530.
19. 19 Deng, J., et al. Targeting epithelial–mesenchymal transition and cancer stem cells for chemoresistant ovarian cancer. Oncotarget 7 (2016), 55771–55788.
20. 20 Weiner-Gorzel, K., et al. Overexpression of the microRNA miR-433 promotes resistance to paclitaxel through the induction of cellular senescence in ovarian cancer cells. Cancer Med. 4 (2015), 745–758.
21. 21 Au Yeung, C.L., et al. Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1. Nature Commun., 7, 2016, 11150.
22. 22 Strandmann, E.P., Müller, R., Shipping drug resistance: extracellular vesicles in ovarian cancer. Trends Mol. Med. 22 (2016), 741–743.
23. 23 Mitra, A.K., et al. Microenvironment-induced downregulation of miR-193b drives ovarian cancer metastasis. Oncogene 34 (2015), 5923–5932.
24. 24 Xu, S., et al. miR-424(322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint. Nat. Commun., 7, 2016, 11406.
25. 25 Peng, J., et al. Chemotherapy induces programmed cell death-ligand 1 overexpression via the nuclear factor-kappaB to foster an immunosuppressive tumor microenvironment in ovarian cancer. Cancer Res. 75 (2015), 5034–5045.
26. 26 Wang, W., et al. Effector T cells abrogate stroma-mediated chemoresistance in ovarian cancer. Cell 165 (2016), 1092–1105.
27. 27 Duluc, D., et al. Interferon-gamma reverses the immunosuppressive and protumoral properties and prevents the generation of human tumor-associated macrophages. Int. J. Cancer 125 (2009), 367–373.
28. 28 Pradeep, S., et al. Hematogenous metastasis of ovarian cancer: rethinking mode of spread. Cancer Cell 26 (2014), 77–91.
29. 29 Perkins, C.L., et al. The role of Apaf-1, caspase-9, and bid proteins in etoposide- or paclitaxel-induced mitochondrial events during apoptosis. Cancer Res. 60 (2000), 1645–1653.
30. 30 Cancer Genome Atlas Research Network, Integrated genomic analyses of ovarian carcinoma. Nature 474 (2011), 609–615.
31. 3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges. Chin. J. Cancer 34 (2015), 4–16.
32. 32 Reinartz, S., et al. Mixed-polarization phenotype of ascites-associated macrophages in human ovarian carcinoma: correlation of CD163 expression, cytokine levels and early relapse. Int. J. Cancer 134 (2014), 32–42.
33. 33 Yu, H., et al. Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat. Rev. Cancer 14 (2014), 736–746.
34. 34 Chaluvally-Raghavan, P., et al. Direct upregulation of STAT3 by microRNA-551b-3p deregulates growth and metastasis of ovarian cancer. Cell Rep. 15 (2016), 1493–1504.
35. 35 Guo, R.X., et al. Increased staining for phosphorylated AKT and nuclear factor-kappaB p65 and their relationship with prognosis in epithelial ovarian cancer. Pathol. Int. 58 (2008), 749–756.
36. 36 Darb-Esfahani, S., et al. Expression of classical NF-kappaB pathway effectors in human ovarian carcinoma. Histopathology 56 (2010), 727–739.
37. 37 Alvero, A.B., Recent insights into the role of NF-kappaB in ovarian carcinogenesis. Genome Med., 2, 2010, 56.
38. 38 Hagemann, T., et al. Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK. J. Immunol. 175 (2005), 1197–1205.
39. 39 Kulbe, H., et al. A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment. Cancer Res. 72 (2012), 66–75.
40. 40 Alberti, C., et al. Ligand-dependent EGFR activation induces the co-expression of IL-6 and PAI-1 via the NFkB pathway in advanced-stage epithelial ovarian cancer. Oncogene 31 (2012), 4139–4149.
41. 41 Godwin, P., et al. Targeting nuclear factor-kappa B to overcome resistance to chemotherapy. Front. Oncol., 3, 2013, 120.
42. 42 Lee, H., et al. Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell 15 (2009), 283–293.
43. 43 Aoudjit, F., Vuori, K., Integrin signaling in cancer cell survival and chemoresistance. Chemother. Res. Pract., 2012, 2012, 283181.
44. 44 Sodek, K.L., et al. Cell-cell and cell-matrix dynamics in intraperitoneal cancer metastasis. Cancer Metastasis Rev. 31 (2012), 397–414.
45. 45 Zhang, H., et al. Integrated proteogenomic characterization of human high-grade serous ovarian cancer. Cell 166 (2016), 755–765.
46. 46 Ohta, T., et al. Inhibition of the Rho/ROCK pathway enhances the efficacy of cisplatin through the blockage of hypoxia-inducible factor-1alpha in human ovarian cancer cells. Cancer Biol. Ther. 13 (2012), 25–33.
47. 47 Chen, S., et al. The involvement of RhoA and Wnt-5a in the tumorigenesis and progression of ovarian epithelial carcinoma. Int. J. Mol. Sci. 14 (2013), 24187–24199.
48. 48 Nyhan, M.J., et al. MiR-193b promotes autophagy and non-apoptotic cell death in oesophageal cancer cells. BMC Cancer, 16, 2016, 101.
49. 49 Geahlen, R.L., Getting Syk: spleen tyrosine kinase as a therapeutic target. Trends Pharmacol. Sci. 35 (2014), 414–422.
50. 50 Yu, Y., et al. Inhibition of spleen tyrosine kinase potentiates paclitaxel-induced cytotoxicity in ovarian cancer cells by stabilizing microtubules. Cancer Cell 28 (2015), 82–96.
51. 51 Kim, Y.J., et al. Activation of spleen tyrosine kinase is required for TNF-alpha-induced endothelin-1 upregulation in human aortic endothelial cells. FEBS Lett. 586 (2012), 818–826.
52. 52 Liou, G.Y., Storz, P., Reactive oxygen species in cancer. Free Radic. Res. 44 (2010), 479–496.
53. 53 Gillet, J.P., et al. Multidrug resistance-linked gene signature predicts overall survival of patients with primary ovarian serous carcinoma. Clin. Cancer Res. 18 (2012), 3197–3206.
54. 54 Shaw, T.J., et al. Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer. Mol. Ther. 10 (2004), 1032–1042.
55. 55 Roby, K.F., et al. Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis 21 (2000), 585–591.
56. 56 Ince, T.A., et al. Characterization of twenty-five ovarian tumour cell lines that phenocopy primary tumours. Nat. Commun., 6, 2015, 7419.
57. 57 Lengyel, E., et al. Epithelial ovarian cancer experimental models. Oncogene 33 (2014), 3619–3633.
58. 58 Perets, R., et al. Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models. Cancer Cell 24 (2013), 751–765.
59. 59 Henao-Mejia, J., et al. Generation of genetically modified mice using the CRISPR-Cas9 genome-editing system. Cold Spring Harb. Protoc., 2016 pdb.prot090704.
60. 60 Yokota, S.J., et al. Changes in ovarian tumor cell number, tumor vasculature, and T cell function monitored in vivo using a novel xenograft model. Cancer Immun., 13, 2013, 11.
61. 61 Bankert, R.B., et al. Humanized mouse model of ovarian cancer recapitulates patient solid tumor progression, ascites formation, and metastasis. PLoS One, 6, 2011, e24420.
62. 62 Kenny, H.A., et al. Mesothelial cells promote early ovarian cancer metastasis through fibronectin secretion. J. Clin. Invest. 124 (2014), 4614–4628.
63. 63 Chang, C.H., et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell 162 (2015), 1229–1241.
64. 64 Liu, X., et al. CD47 blockade triggers T cell-mediated destruction of immunogenic tumors. Nat. Med. 21 (2015), 1209–1215.
65. 65 Lo, J., et al. Anti-CD47 antibody suppresses tumour growth and augments the effect of chemotherapy treatment in hepatocellular carcinoma. Liver Int. 36 (2016), 737–745.
66. 66 Chester, C., et al. Immunotherapeutic approaches to ovarian cancer treatment. J. Immunother. Cancer, 3, 2015, 7.
67. 67 Nieman, K.M., et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat. Med. 17 (2011), 1498–1503.
68. 68 Patch, A.M., et al. Whole-genome characterization of chemoresistant ovarian cancer. Nature 521 (2015), 489–494.
69. 69 Lu, Z., et al. DIRAS3 regulates the autophagosome initiation complex in dormant ovarian cancer cells. Autophagy 10 (2014), 1071–1092.
70. 70 Liao, J., et al. Ovarian cancer spheroid cells with stem cell-like properties contribute to tumor generation, metastasis and chemotherapy resistance through hypoxia-resistant metabolism. PLoS One, 9, 2014, e84941.
71. 71 Ip, C.K., et al. Stemness and chemoresistance in epithelial ovarian carcinoma cells under shear stress. Sci. Rep., 6, 2016, 26788.
72. 72 Correa, R.J., et al. Modulation of AKT activity is associated with reversible dormancy in ascites-derived epithelial ovarian cancer spheroids. Carcinogenesis 33 (2012), 49–58.
73. 73 Zhang, L., et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348 (2003), 203–213.
74. 74 Hwang, W.T., et al. Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecol. Oncol. 124 (2012), 192–198.
75. 75 Curiel, T.J., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10 (2004), 942–949.
76. +/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc. Natl. Acad. Sci. U. S. A. 102 (2005), 18538–18543.
77. 77 Gubin, M.M., et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515 (2014), 577–581.
78. 78 Abiko, K., et al. PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction. Clin. Cancer Res. 19 (2013), 1363–1374.
79. 79 Nirschl, C.J., Drake, C.G., Molecular pathways: coexpression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy. Clin. Cancer Res. 19 (2013), 4917–4924.
80. 80 Hamanishi, J., et al. Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J. Clin. Oncol. 33 (2015), 4015–4022.
81. 81 Gaillard, S.L., et al. The role of immune checkpoint inhibition in the treatment of ovarian cancer. Gynecol. Oncol. Res. Pract., 3, 2016, 11.
82. 82 Jansen, V.M., et al. Is there a future for AKT inhibitors in the treatment of cancer?. Clin. Cancer Res. 22 (2016), 2599–2601.
83. 83 Furtek, S.L., et al. Strategies and approaches of targeting STAT3 for cancer treatment. ACS Chem. Biol. 11 (2016), 308–318.
84. 84 Saini, U., et al. Elevated STAT3 expression in ovarian cancer ascites promotes invasion and metastasis: a potential therapeutic target. Oncogene, 2016, 10.1038/onc.2016.197 Published online June 13, 2016.
85. 85 Chen, D., et al. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Curr. Cancer Drug Targets 11 (2011), 239–253.
86. 86 Aghajanian, C., et al. Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer. J. Clin. Oncol. 23 (2005), 5943–5949.
87. 87 Parma, G., et al. An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens. Int. J. Gynecol. Cancer 22 (2012), 792–800.
88. 88 Niewerth, D., et al. Interferon-gamma-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines. J. Hematol. Oncol., 7, 2014, 7.
89. 89 Singha, B., et al. IKK inhibition increases bortezomib effectiveness in ovarian cancer. Oncotarget 6 (2015), 26347–26358.